YCBDcbdMD, Inc.
Next earnings Aug 12, 2026 · consensus $-0.03 EPS, $5.80M rev
$0.79
▼ -2.80%AvoidConservative balance sheet (liabilities/equity 0.44x); but revenue declined -1.5% YoY.Revenue (FY2025) $19.2MFull call ↓
$0.79▼ -8.77%
over 1Y
L $0.47H $2.27
Our buy Our hold Our sell Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today
-2.8%
1W
+10.6%
1M
+13.8%
3M
+15.8%
YTD
-32.1%
1Y
-8.8%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity 0.44x); but revenue declined -1.5% YoY.
Revenue (FY2025) $19.2M · FY2025
This call stands until the filings change it — the engine re-rates on new 10-K/10-Q/8-K facts, never on price moves. Hit Watch above to follow YCBD (Pro alerts fire the moment a rating flips), or catch every change in Saturday’s Flip Side. How to read a call
cbdMD, Inc. shows $19.2M in FY2025 revenue (-1.5% YoY), a -10.6% net margin, and -28.2% ROE.
Supporting the case: conservative balance sheet (liabilities/equity 0.44x).
Is YCBD a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread (caution)~60d expiry
- Long put 1 @ ~0.23 est
- Short put 0.5 @ ~0.00 est
debit $23max +$27max −$23BE 0.77
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financialsannual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $44.5M | $35.4M | $24.2M | $19.5M | $19.2M |
| Gross profit | $30.0M | $22.3M | $15.0M | $12.0M | $12.0M |
| Operating income | -$19.6M | -$78.3M | -$22.5M | -$3.32M | -$2.16M |
| Net income | -$23.4M | -$70.1M | -$22.9M | -$3.70M | -$2.04M |
| Diluted EPS | -$0.47 | -$55.80 | -$13.32 | -$14.29 | -$1.09 |
| Net margin | -52.6% | -198.0% | -95.0% | -19.0% | -10.6% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$6.34M
EV / EBITDA—
EV / Sales0.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-23.7%
FCF yield-19.0%
Quality & risk
ROIC (est.)-23.6%
Free cash flow-$1.64M
Total debt$9.00
Net cash$2.26M
Altman Z-Score-20.95 distress
Piotroski F-Score6/9
Capital returns
Buyback yield—
Dividend yield (est.)29.7%
Shareholder yield29.7%
Shares Δ YoY+70.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timelineSEC · 8-Ks + reports
Red flag in recent filings — restated periodic report (2026-01-20). Worth a closer look.
- 8-K Material agreement2026-05-20
- 10-Q Quarterly report2026-05-14
- 8-K Other event2026-04-15
- 8-K Officer / director change2026-04-01
- S-1/A Securities registration2026-02-20
- 10-Q Quarterly report2026-02-17
- DEF 14A Proxy statement2026-02-12
- S-1 Securities registration2026-01-22
- 10-K/A Restated periodic report2026-01-20
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-05-202026-05-20open ↗10-QPeriod ending 2026-03-312026-05-14open ↗4Period ending 2026-04-142026-04-16open ↗4Period ending 2026-04-142026-04-16open ↗4Period ending 2026-04-142026-04-16open ↗4Period ending 2026-04-142026-04-16open ↗4Period ending 2026-04-142026-04-16open ↗4Period ending 2026-04-142026-04-16open ↗8-KPeriod ending 2026-04-142026-04-15open ↗8-KPeriod ending 2026-03-302026-04-01open ↗EFFECTFiling2026-03-04open ↗424B4Filing2026-03-04open ↗
Frequently asked
- Is cbdMD, Inc. (YCBD) a buy?
- YCBD currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.44x); but revenue declined -1.5% YoY.
- What is cbdMD, Inc.'s quality score?
- YCBD scores 54.11387962962963/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001644903, latest 10-Q filed 2026-05-14) · EODHD · as of 7/11/2026, 9:24:32 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 11, 2026, 5:24 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
SEC correspondence
SEC · UPLOAD / CORRESPSEC staff comment letters (UPLOAD) questioning the company’s disclosures and its written responses (CORRESP), from the SEC’s filing review. Reviews are routine and this is not an assertion of wrongdoing; correspondence is released about 20 business days after a review concludes, so dates reflect the letter itself, not its release. Source: SEC EDGAR (public domain).